EMILY ADAMS: Open Payments
NPI 1710060033 · GREENCASTLE, IN. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$899 in 49 payments from 12 companies in 2025. Trend: 2023 $672 · 2024 $948 · 2025 $899
Food & beverage: $899
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 10 | $179 |
| Axsome Therapeutics, Inc. | 8 | $164 |
| Amgen Inc. | 9 | $138 |
| Novo Nordisk Inc | 5 | $90 |
| AstraZeneca Pharmaceuticals LP | 3 | $55 |
| Lilly USA, LLC | 3 | $54 |
| GlaxoSmithKline, LLC. | 3 | $49 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 2 | $44 |
| Corium, LLC | 2 | $42 |
| Bayer Healthcare Pharmaceuticals Inc. | 2 | $42 |
Products named: Auvelity, OTEZLA, QULIPTA, VRAYLAR, Wegovy, CAPLYTA, Azstarys, Kerendia.
Industry payments across IN — which companies pay providers there.
